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Peroxisome Proliferator-Activated Receptor-γ (PPARγ) is a ligand-activated nuclear hormone receptor that 
functions as transcription factor and plays an important role in lipid metabolism and insulin sensitization. Recent 
studies have shown that PPARγ is over-expressed in many tumor types, including cancers of breast, lung, 
pancreas, colon, glioblastoma, prostate and thyroid differentiated/anaplastic cancers. These data suggest a role 
of PPARγ in tumor development and/or progression. PPARγ is emerging as a growth-limiting and 
differentiation-promoting factor, and it exerts a tumor suppressor role. 
Moreover, naturally-occurring and synthetic PPARγ agonists promote growth inhibition and apoptosis. 
Thiazolidinediones (TZDs) are synthetic agonists of PPARγ that were developed to treat type II diabetes. These 
compounds also display anticancer effects which appear mainly to be independent of their PPARγ agonist 
activity. Various preclinical and clinical studies strongly suggest a role for TZDs both alone and in combination 
with existing chemotherapeutic agents, for the treatment of cancer.  
Differentiation therapy involves the use of agents with the ability to induce differentiation in cells that have lost 
this ability, i.e. cancer cells, targeting pathways capable of re-activating blocked terminal differentiation 
programs. PPARγ agonists have been shown to induce differentiation in solid tumors such as thyroid 
differentiated/anaplastic cancers and sarcomas. 
However, emerging data suggest that chronic use of TZDs is associated with increased risk of adverse 
cardiovascular events. The exploration of newer PPARγ agonists can help in unveiling the underlying 
mechanisms of these drugs, providing new molecules that are able to treat cancer, without increasing the 
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In humans Peroxisome Proliferator-Activated Receptor-γ (PPARγ) is a type II nuclear receptor, encoded by the 
PPARg gene [1]. Its endogenous ligands are free fatty acids and eicosanoids. Once activated, the receptor binds 
to DNA in complex with the retinoid X nuclear receptor (RXR), increasing or decreasing the transcription of 
specific genes. PPAR-α, PPAR-δ, and PPAR-γ are the known three PPARs subtypes. PPAR-γ regulates glucose 
metabolism and fatty acid storage, stimulates lipid uptake and adipogenesis by fat cells, and is a regulator of 
adipocyte differentiation [2]. In humans and mice, two isoforms of PPAR-γ are detected: PPAR-γ1 (present in 
almost all tissues, except muscle) and PPAR-γ2 (in adipose tissue and intestine) [3]. PPAR-γ is involved in the 
pathogenesis of different diseases: obesity, diabetes, atherosclerosis, and cancer. Its agonists are implicated in 
the treatment of hyperlipidaemia and hyperglycemia [4]. PPAR-γ decreases the inflammatory response of many 
cardiovascular cells, mainly endothelial cells [5], reduces atherosclerosis, activating the PON1 gene, that 
increases the synthesis and release of paraoxonase 1 from the liver [6].  
PPAR-γ are also involved in autoimmune disorders [7] and in cancerogenesis [8], too.  
The PAX8-PPAR-γ1 fusion is present in approximately one-third of follicular thyroid carcinomas, that show the 
chromosomal translocation of t(2;3)(q13;p25), by juxtaposition of portions of both genes [9]. Furthermore, 
PPAR-γ is the target of various insulin sensitizing drugs involved in the treatment of diabetes. 
  
1.1. Thiazolidinediones (TZDs) and “partial agonists of PPAR-γ” 
TZDs (or glitazones) are drugs implicated in the treatment of diabetes mellitus type 2. TZDs activate PPARs, 
with greatest specificity for PPAR-γ. Once activated, the PPAR/RXR heterodimer binds to peroxisome 
proliferator hormone response elements upstream of target genes, complexed with coactivators, as nuclear 
receptor coactivator 1 and CREB binding protein, upregulating the target genes. The activation of PPAR-γ 
causes: 1) decrease of insulin resistance; 2) change in insulin secretion in β-cells [10]; 3) modification in 
adipocyte differentiation; 4) fall of certain cytokines/chemokines levels [11,12]; 5) antiproliferative action. 
Moreover, TZDs increase the synthesis of particular proteins implicated in fat metabolism, decrease 
triglycerides and increase high-density cholesterol. The “partial agonists of PPAR-γ” are other classes of 
compounds able to activate PPAR-γ, but weaker than TZDs. At the present, these compounds are studied, 
hoping that they could be effective hypoglycemic agents but with fewer side effects [13,14]. 
 
1.2. Epidemiologic evidence of TZD anti-cancer activity 
 
Different epidemiological studies have demonstrated the TZDs antineoplastic effect. Pancreatic cancer cases 
decreased significantly in patients administered with rosiglitazone (RGZ) with respect to controls, as evidenced 
by a survey trial conducted in patients with diabetes [15]. 
A meta-analysis conducted in 30,000 patients showed a reduced incidence of cancer in diabetic patients 
administered with RGZ [16], and another meta-analysis [17] suggested that the treatment with TZDs was 
associated with a slight significantly decrease of risk of lung and breast cancers. This has been confirmed by a 
6-years population-based cohort study, showing a decrease in different cancer risk in diabetic patients treated 
with TZDs, and that the association was dose-dependent [18]. Though encouraging preclinical results, 
favourable effects were not always been shown by clinical trials. Anyway, troglitazone (TGZ) stabilized the 
prostate-specific antigen (PSA) serum levels in advanced prostate cancer in a phase II trial [19]. 
 
1.3. PPARγ-dependent and -independent antitumor effects of TZDs 
Different human cancer cell lines exhibit high levels of PPARγ expression, and their in vitro exposure to 
elevated doses (≥ 10 µM) of TZDs, particularly TGZ and ciglitazone (CGZ), led to cell cycle arrest, apoptosis 
and/or redifferentiation [20-24], suggesting a putative link between PPARγ signaling and TZD’s antitumor 
activities. The in vivo anticancer effect of TGZ was shown in a few clinical cases in patients with liposarcomas 
[25] or prostate cancer [26]. Until now, the specific target genes contributing to the antiproliferative effects of 
PPARγ agonists are not clear, as the genomic responses to PPARγ are complex and depend on the cellular 
context in the different types of cancer [21]. In colorectal cancer cells PPARγ-specific target genes included 
those associated with growth regulatory pathways, colon epithelial cell maturation, immune modulation, and 
intercellular adhesion [27]. Even the functional role of the PPARγ-specific target genes in modulating TZDs’ 
antiproliferative effects in cancer cells is still not clear. 
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On the other hand, not all authors agree on the fact that the antitumor effect of TZDs depends on PPARγ 
activation, as: 1) TZDs’ antitumor effects seem to be structure-specific regardless of the potency in PPARγ 
activation [TGZ and CGZ are more active in inducing apoptosis in cancer cells compared to RGZ and 
pioglitazone (PGZ)]; 2) A 3-orders-of-magnitude discrepancy is present between the necessary concentration to 
mediate antitumor effects and that for activating PPARγ; 3) A correlation between the susceptibility of tumor 
cells to TZDs and the PPARγ expression level does not exist, as for example, LNCaP prostate cancer and MCF-
7 breast cancer cells, that have low PPARγ expression levels, were more sensitive to the effects of TGZ and 
CGZ on suppressing cell viability than PC-3 and MDA-MB-231 cells, that over-express PPARγ [28,29]; 4) the 
PPARγ-inactive analogues of TGZ and CGZ, Δ2-TG and Δ2-CG, were slightly more effective than their parent 
compounds in suppressing cell proliferation in cancer cells [28,29]; 5) Knocking down PPARγ by siRNA in PC-
3 cells, the ability of TGZ or Δ2-TG to induce apoptotis was not affected [8].  
 
1.4. The TZDs induction of apoptosis 
 
In prostate cancer cells, the induction of cytochrome c release and DNA fragmentation was stronger with Δ2-
TGZ and Δ2-CGZ than TGZ and CGZ while minor effects were shown with powerful PPARγ agonists, as RGZ 
and PGZ and their Δ2 derivatives [28]. The TZD-induced apoptosis depends on caspases via intrinsic and 
extrinsic pathways. As an example, the dual PPARα/PPARγ agonist TZD18 is able to inhibit cell proliferation 
indipendently from PPARγ, and to induce apoptosis in SD1 and BV173 leukemic cells, by cleavage of caspases-
8 and -9. The pan-caspase inhibitor Z-VAD-FMK blocked this activity [30]. The cleavage of caspase-9, -8 and -
3 was stimulated also by TGZ in a PPARγ-independent manner in bladder cancer T24 and RT4 cells, as the 
apoptosis, specifically blocked by certain caspase inhibitors [31]. The same data were shown in T24 bladder 
cancer cells with CGZ [32]. In MCF-7 and MDA-MB-231 breast cancer cells, the mitochondrial membrane 
potential was modified by Δ2-TGZ, that also induced the cleavage of PARP and caspase-7 (stopped by Z-VAD-
FMK) [33]. The expression of Bcl-2 family members was modulated by TZDs, stimulating the intrinsic pathway 
of apoptosis. TZD18 up-regulated the proapoptotic protein Bax in human leukaemia cells but did not change the 
anti-apoptotic Bcl-2 expression [30], while in MCF-7 and MDA-MB-231 breast cancer cells it up-regulated Bax 
and Bak [34]. The Bax/Bcl2 mRNA ratio was increased by TGZ in renal carcinoma cells, while it did not 
change the Bcl-2 members expression in PC-3 prostate cancer cells [28, 35]. Anyway, TGZ, CGZ and their Δ2 
derivatives blocked the heterodimerization of Bcl-2 and Bcl-XL with Bax, inhibited the anti-apoptotic action, 
and activated cytochrome c release and caspase-9 [28]. Bcl-XL over-expression protected the PPARγ-deficient 
LNCaP cells against the apoptosis induced by TGZ and its Δ2 counterpart [28]. It has been recently shown that 
TZD activates the membrane G protein-coupled receptor 40 [36], leading to osteocyte apoptosis recruiting Bax 
to the outer mitochondrial membrane.  
The inactive PPARγ derivative of D2-CGZ, OSU-CG12, exhibited its anticancer effect in prostate and breast 
cancer cells inducing apoptosis, through the cleavage of PARP, and the proapoptotic proteins ATF3, Noxa and 
DAPK2 increased. PARP cleavage was shown in OSU-CG30- exposed LNCaP cells, too [37]. In MDA-MB-
231 and MDA-MB-468 (breast cancer cell lines), OSU-53 induced apoptosis through PARP-cleavage and rises 
in the sub-G1 apoptotic population [38]. The cleavage of PARP was also shown in vivo in nude mice in OSU-
53-treated MDA-MB-231 tumors, while it did not stimulate PARP cleavage in the control MCF-10A cells. TZD 
exerts its effects also combined with other treatments. For example, TZD sensitized cancer cells to the apoptosis 
induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [31,39–42]. In lung cancer cells 
treated with the combination of TRAIL and TZD, the cleaved forms of PARP and caspase-8, -9 and -3 were 
evidenced much more easily with respect to the treatment with each of them alone [41]. TZD induces apoptosis 
via TRAIL increasing DR5 expression and down-regulating cellular Flice-like inhibitor protein (c-FLIP) [43] or 
survivin [31,40–42]. In lung cancer, the over-expression of c-FLIP and silencing of DR5 expression through 
RNA interference abolished the induction of apoptosis by TRAIL by PPARγ ligand [41]. Furthermore, TGZ and 
CGZ up-regulated TRAIL expression in TRAIL-resistant T24 bladder cancer cells and increased apoptosis by 
TRAIL activating death receptor signaling pathways [31,32]. 
 
1.5. The TZDs induction of autophagy 
TGZ induced autophagy in HeLa cells, evidenced by AMPK phosphorylation, LC3-II increase and degradation 
of sequestome 1 (SQSTM1/p62; a selective substrate of autophagy), participating in the apoptosis via caspases 
[44]. TGZ supported autophagosome creation and an increase in LC3-II in porcine aortic endothelial cells, too 
[45], related to AMPK phosphorylation and independently from PPARγ. Moreover, RGZ and TGZ induced 
autophagy activating PPARγ in MDA-MB-231 breast cancer cells [46]. RGZ inhibited cell proliferation 
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independently or not from PPARγ and provoked an autophagic process, increasing p-AMPK and the expression 
of beclin-1, in H295R adrenocortical cancer cells [47]. RGZ-induced autophagy depends on the cellular context, 
as this was not shown in SW13 adrenocortical cancer cells. In H295R cancer cells it was associated with the 
production of reactive oxygen species (ROS) and the disruption of the mitochondrial membrane potential [47]. 
Nutrient-deprivation autophagy factor-1 (NAF-1) and CDGSH iron sulfur domain 1 protein (mitoNEET) 
(members of NEET protein family) are determinant in maintaining the mitochondrial integrity, cellular iron and 
ROS homeostasis. NAF-1 and mitoNEET increase in MCF-7, MDA-MB-468 and HCC-70 human epithelial 
breast cancer cells with respect to the control MCF-10A. Knocking-down these proteins by small hairpin 
(sh)RNA in MCF-7 and MDA-MB-231 breast cancer cells decreases significantly cell proliferation and tumor 
growth, the mitochondrial membrane potential, and causes the increase of ROS in mitochondria and autophagy 
[48]. For these reasons, NAF-1 and mitoNEET could be considered TZDs mitochondrial targets [49–51]. 
OSU-CG12 induced autophagy in LNCaP prostate cancer cells, as shown by the increase of LC3-II in 
autophagic vacuoles, inducing AMPK phosphorylation upon 10min from exposure, down-regulation of mTOR 
and p70S6K phosphorylation. The expression of a dominant-negative form or the use of pharmacological agents 
inhibited the AMPK function, preventing the conversion from LC3-I to LC3-II and autophagy. This process 
decreased the action of OSU-CG12 on cell viability in LNCaP cells, but it did not have effects on PARP 
cleavage. OSU-53 stimulated a protective autophagy that weakened its antiproliferative effect [38]. If MDA-
MB-231 cells expressed an AMK dominant-negative form, OSU-53 had effects on cell viability to a lesser 
extent. Its combination with the autophagy inhibitor chloroquine induced the in vitro antiproliferative effect and 
the in vivo tumor-suppressive effects of this compound [38].  
 
1.6. TZDs as energy restriction mimetic agents (ERMAs) 
 
Some TZDs behave as ERMAs, and this was confirmed for OSU-CG12 in LNCaP cells, that were protected 
from the cell death induced by this compound by elevated levels of supplemental glucose. OSU-CG12 provoked 
cellular responses characteristic of energy restriction in LNCaP and MCF-7 cells at 5 µM with respect to 5 mM 
for 2-DG. OSU-CG12 reduced glycolytic rate and intracellular lactate and NADH, and in this way the different 
ATP/AMP ratio induced AMPK activation. A slight fall in [3H]2-DG uptake can be seen after less than 20 min 
of OSU-CG12 exposure. After 24 h of treatment with OSU-CG12, RT-PCR analyses showed a fall in mRNA 
levels of the first 2 enzymes of the glycolytic pathway, hexokinase 2 and phosphofructokinase-1. In these cells 
OSU-CG5 suppressed [3H]-2DG uptake more strongly (IC50 = 6 µM) than OSU-CG12 (IC50 = 9 µM). The 
OSU-CG5-optimized OSU-CG30 was able to block glucose uptake into LNCaP cells (IC50 = 2.5 µM) [37], 
thanks to its capacity of binding to the GLUT1 channel at a different site than glucose [37].  
In C-26 colon adenocarcinoma cells, OSU-53 stimulated AMPK phosphorylation and decreased p70S6K [52]. 
OSU-53 induced kinase activity with an EC50 of 0.3 µM with respect to 8 µM for AMP, as shown by 
radiometric kinase assays conducted using a recombinant AMPK α1β1γ2 [38]. In breast cancer, OSU-53 
decreased viability and clonogenic growth of MDA-MB-468 (LKB1 positive) and MDA-MB-231 (LKB1 
negative) with a similar strenght, while it did not have effects in nonmalignant MCF-10A cells. This data 
confirmed a direct activation of AMPK and not a LKB1-mediated process. Multiple AMPK downstream 
pathways are OSU-53 targets [38]. The temporary induction of Sirt1, proteolysis and endoplasmic reticulum 
(ER) stress are the key starvation-associated responses to these compounds. Each of them modulates a different 
signaling pathway linked to the anti-proliferative effects. 
 
1.7. Sirt1/β-TrCP-dependent proteolytic events induced by TZDs 
 
As after 2-DG-exposure, the temporary increase of Sirt1 expression in OSU-CG12-treated cells was determinant 
for the induction of apoptosis, as it increased β-TrCP through its stabilization, down-regulating β-TrCP-specific 
E3 ligase Skp2 expression. This resulted in an inferior ubiquitin-dependent β-TrCP degradation, that led to 
proteasomal degradation of different cell cycle and apoptosis regulatory proteins, as β-catenin, cyclin D1 and 
Sp1 [53,54]. The down-regulated Sp1 induced the transcriptional repression of histone deacetylases and H3K4 
demethylases leading to an epigenetic effect of the tumor suppressor KLF6, important for the induction of 
apoptosis. 
OSU-CG5 up-regulated “DNA methylation-silenced tumor suppressor genes” and down-regulated “methylated 
tumor/invasion-promoting genes”, owing to transcriptional repression of DNMT-1. Also OSU-CG30 led to 
apoptosis, inducing cellular responses dependent on ERMAs, as β-TrCP-mediated protein degradation 
[cyclinD1, Sp1] and epigenetic activation of KLF6 [37]. 
6 
 
1.8. ER stress induction 
 
As after 2-DG-exposure, also OSU-CG12 induced ER stress. Upon 6 h of exposure to OSU-CG12 10 µM, 
phosphorylation of eIF2α at Ser51 occurred, and after 48 h to 5 µM, an up-regulation of IRE-1α and the 
chaperone GRP78 were shown in LNCaP cells. Also up-regulation of C/Ebp-Homologous Protein (CHOP) was 
observed, that seemed to appear only in the case of treatment with higher doses (10–20 µM), and whose 
silencing did not affect the susceptibility to the antiproliferative effect of OSU-CG12 and PARP cleavage. OSU-
CG12 was more potent in its anti-proliferative effect than 2-DG and resveratrol, as its energy restriction-
associated responses were reached at 5 µM with respect to 5 mM and 100 µM for 2-DG and resveratrol, 
respectively. Furthermore, it had low toxicity against nonmalignant prostate epithelial cells where neither effect 
could be shown on β-TrCP or Sp1. The apoptosis induced by OSU-CG12 did not seem to be mediated by ER 
stress [43].  
In colorectal cancer HCT-116 and Caco-2 cells, the ER stress response proteins GRP78 and GADD153/CHOP 
levels were increased by OSU-CG5 [55]. 
The major part of the TZDs anticancer effects are PPARγ-independent, and for this reason different derivatives 
belonging to the D2 family were synthesized, with a double bound next to the terminal thiazolidine-2,4-dione 
ring, lacking PPARγ agonist activity, but still displaying anticancer effects. For example, D2-TGZ affected 
breast cancer cells viability [56]. Most of D2-TGZ-derivatives were functionalized on the terminal hydroxyl 
group of the chromane moiety, and showed a stronger activity on breast cancer cell viability [57]. Some of them 
had good antiproliferative effects in breast cancer cells and low toxicity in human hepatocytes [58]. D2-TGZ 
and D2-CGZ inhibited prostate cancer cells proliferation more strongly than their parent compounds, in PPARγ-
expressing PC-3 and PPARγ-deficient LNCaP cells [28]. The permutational rearrangement of the OSU-CG12 
terminal methylcyclohexylmethyl moiety caused the formation of an inverted molecule, with the TZD ring in 
the middle, and in which the phenyl ring was functionalized by a trifluoroacetate group [59]. Upon oral 
administration to male transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, OSU-CG5 blocked 
prostate epithelial growth and preneoplastic lesions [60].  
 
1.9. Therapeutic efficacy of TZDs in specific cancers 
 
CGZ, TGZ, RGZ, and PGZ induce a decrease of cell proliferation, cytotoxicity, and proapoptotic effects in 
different cell lines [sarcoma, melanoma, glioblastoma, breast carcinoma, colorectal cancer, gastric cancer, 
pancreatic cancer, prostate, bladder cancer, hepatic cancer, thyroid cancer (TC), ovarian cancer, endometrial 
cancer, and lung cancer cells, etc.]. Thanks to the good results obtained in vitro, animal experiments and clinical 
trials have been conducted. 
In some of these cancer types, efatutazone (EFA), developed as a chemostatic rather than an antidiabetic drug, 
has been evaluated. EFA is a PPARγ activator 500 times more potent than TGZ and 50 times than RGZ. It was 
studied in a preclinical murine model for breast cancer based on BRCA1 (BReast CAncer 1) deficiency. In the 
Mouse Mammary Tumor Virus (MMTV)-Cr BRCA1flox/flox p53+/− model, exon 11 of the BRCA1 gene is 
deleted by MMTV-Cre transgene, causing a loss of one germline copy of TP53. EFA reduced the incidence of 
non-invasive and well-differentiated tumors in this model [61]. Administration of EFA reduced cell proliferation 




Phase I trials were then started as monotherapy or combined with other compounds.  
Stable disease (SD) was induced in 10/22 patients with advanced liposarcoma after monotherapy [63].  
A phase I study evaluating the combination of bexarotene with EFA in solid tumors has been conducted 
(NCT01504490). 
The first trial evaluating the antitumor effects of the antidiabetic TZDs was conducted in 3 liposarcoma patients, 
and TGZ led to a reduced proliferation [25], while there were no beneficial effects in a trial with RGZ in 9 
liposarcoma patients [64]. Though the negative results obtained from this trial, another phase II trial on RGZ is 
ongoing (NCT00004180; http://www.cancer.gov/clinicaltrials/).  
 
1.9.2. Colorectal Cancer 
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PPARγ expression shows protective effects in colorectal cancer, as evidenced by studies on human tumor 
samples [65]. Patients with PPARγ expression usually showed a better prognosis, in fact the reduction of β-
catenin and PPARγ was correlated with elevated numbers of tumor-associated macrophages, increased 
metastasis, and poor survival [66]. Loss of function point mutations of the PPARγ gene and polymorphisms 
were reported in 8% of colorectal carcinoma patients. However, some studies on PPARγ expression in 
colorectal samples did not find any relation between PPARγ immunoreactivity and tumor aggressiveness 
[67,68].  
TZDs showed variable effects in vivo. In mice the activation of PPARγ inhibited xenograft growth and its 
agonists reduced the number of aberrant cryptal foci in chemically induced inflammatory bowel disease [69,70]. 
PGZ induced increased polyp numbers in mice with APC mutation, susceptible to colon adenoma (APCmin), 
but not in wild-type mice, leading to hypothesize that TZDs could also promote colon cancer development [71]. 
These dissimilar results might be explained by in vitro studies in colon cancer cell lines, which evidenced that 
PPARγ expression correlated to cells’ sensitivity to proliferation inhibition [72]. A phase II trial with TGZ did 
not increase progression-free survival in 25 colorectal cancer patients [73]. 
 
1.9.3. Lung Cancer  
 
As PPARγ expression in well-differentiated lung adenocarcinoma was higher than in poorly differentiated 
tumors, it was hypothesized that it promotes tumor formation, even if it is not a marker for aggressive growth 
[74]. However, in another paper it was shown the opposite trend, as the expression was linked to poor prognosis 
[75]. RGZ decreased progression of chemically induced murine cancer model [76]. 
 
1.9.4. Breast Cancer 
 
In breast cancer cells PPARγ mRNA levels did not correlate with nodal involvement and tumor grade, but 
significantly lower PPARγ levels were shown in large metastatic tumors, patients with local recurrence and poor 
survival [77]. TZDs had moderate positive effects in breast cancer models. RGZ decreased tumor growth in a 
chemically induced rat and in a syngenic murine tumor model [78,79]. Treating with TZDs patients with 
advanced breast carcinoma and with early mammary cancer did not lead to therapeutic effects [80,81]. 
 
1.9.5. Prostate Cancer 
 
Immunoreactivity and PPARγ expression correlated inversely with tumor size and PSA levels in most of 
prostate cancers (73%) [82]. Data obtained in prostate cancer xenografts as well as results from a phase II trial 




Gliomas did not show any correlation with PPARγ expression [84]. However, patients with diabetes mellitus 
administered with TZD showed lower incidence of high-grade glioma than controls (patients with hip fractures), 
while survival of patients with glioma was similar in both groups [85]. The efficacy of PGZ has been shown in 




No correlation of PPARγ expression and melanoma prognosis was evidenced [88]. In a cohort study conducted 
in patients with diabetes mellitus under PGZ therapy, an increased hazard ratio for melanoma (1.3) was shown 
[89]. It is not clear whether these data represent an increased incidence of tumors because the maximum 
duration of follow-up was < 6 years after the initiation of PGZ. Studies on monotherapy with TZDs in 
melanoma are restricted, as only CGZ inhibited growth of melanoma xenografts [90]. 
PPARγ seems to have a protective effect in tumor development, as elevated mRNA or protein expression in 
well-differentiated tumors compared to poorly differentiated tumors and tumors with poor prognosis has been 
shown [63]. 
 
1.10. TZDs in Differentiated Thyroid Carcinoma (DTC) 
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Follicular thyroid cancer (FTC) is the only known neoplasm associated with a PPARγ fusion gene product [91], 
PAX8/PPARγ, that is expressed in 30–35% of FTC and 2–13% of follicular adenomas [92]. This chimeric 
protein derives from a genetic translocation between chromosomes 2 and 3 and is able to activate the PPARγ 
response element inducing proliferation. It functions as a gain and loss of function mutant determining thyroid 
tumor differentiation; in more aggressive tumors gain of function predominates [91]. 
In the last decades, TC incidence in the United States has increased [93].  
The increasing diagnosis of TC is related to the use of neck ultrasonography for the diagnosis of thyroid 
nodules, but also to ionizing radiations [94], the exposure to fall-out of nuclear accidents [95], the exposure to 
iodine deficiency that increases frequency of FTC [96]. Furthermore, autoimmune thyroiditis has been shown to 
be a risk factor for papillary thyroid caner (PTC) [97,98], and new risk factors are emerging [99-101]. 
DTC (mainly PTC) is the most common type of thyroid carcinoma, accounting for 80–90% of all TCs. FTCs is 
the 2nd most common, with 10–15% incidence. The prognosis of DTC is frequently good, with a 10-year 
survival rate of 85% [102]. Approximately 10–20% of patients develop distant metastases [103], showing a 10-
year survival rate of 40%. Recurrence in DTC occurs in not less than a third of patients and only 30% of patients 
with distant metastases respond to radioiodine (RAI) therapy with complete remission [104,105]. DTC first-line 
therapy is total or near total thyroidectomy and lymph node dissection (if necessary). RAI treatment commonly 
follows, for thyroid remnant ablation and elimination of metastases. In case of inefficacy of these treatments, 
doxorubicin follows [106]. As doxorubicin is not strongly efficient, in the future differentiating therapies will 
play a determinant role in cancer treatment. Redifferentiating compounds include retinoids, histone deacetylase 
inhibitors, DNA methyltransferase inhibitors, and TZDs. Somatostatin analogues (for example, 68Ga-
DOTATOC) are additional options for RAI-negative TC [107]. 
PGZ and CGZ did not increase differentiation in the human PTC cell line NPA [108], while TGZ, RGZ, and 
PGZ showed antiproliferative, proapoptotic, and differentiating effects on DTC cells in another paper [63,109]. 
TGZ increased expression of sodium-iodide symporter in DTC lines [110] and restored RAI-uptake in vitro 
[111].  
PGZ reduced metastatic disease in a tumor model where the effect of PAX8/PPARγ fusion protein is mimicked 
[112]. RGZ reduced thyrocyte growth by 40% in a murine knock-in model of thyroid hormone receptor γ [113]. 
TZDs modulate chemokine secretion in TC. In fact, a dysregulation of chemokine CXCL10 secretion has been 
shown in PTCs. A CXCL10 secretion more than ten times higher has been induced by IFNγ+TNFα in PTCs 
with respect to control thyroid follicular cells (TFC). Moreover, TZDs inhibited CXCL10 secretion in control 
TFC while stimulated it in PTCs. The effect of TZDs on CXCL10 was unrelated to the significant 
antiproliferative effect in PTCs [114,115]. 
TZDs were also evaluated in patients with TC. In 5 patients treated with PGZ for 6 months, no increase in RAI-
uptake was observed [116]. An effective induction of RAI-uptake after RGZ therapy was reported by 2 case 
reports, in patients with non-iodide avid metastases of DTC [117,118]. The results of treatment showed reduced 
thyroglobulin levels and tumor size. An increased RAI-uptake after RGZ treatment was shown in 1/5 patients 
enrolled in a pilot study [119], while another paper reported positive RAI scans in 4/10 patients after RGZ 
treatment [120]. A clinical trial showed increased RAI-uptake in therapeutic 131I scans in 5/23 patients [121]. 
In another phase II trial, though reinduction of RAI-uptake in 5/20 patients, none had a complete or partial 
response (PR) to RGZ after 3 months [122] by RECIST criteria [123]. A current trial (NCT00098852) with 
RGZ for reinduction of RAI-uptake is still ongoing (http://www.clinicaltrial.gov/). The redifferentiating action 
of PGZ is being reassessed in a trial focused on follicular variants of PTC (NCT01655719; 
http://www.clinicaltrial.gov/). The restricted accuracy of the 131I scans technique, the unknown status of 
receptor expression of the treated tumors, too low levels of expression by the target cells, inhomogeneity of 
RAI-uptake into the tumor, and the generally poor correlation between RAI-uptake and clinical remission, make 
the interpretation of the obtained data quite difficult. Moreover, an observation time shorter than 1 year could 
not be enough to monitor effects in slow-growing DTC.  
Recently epidemiologic, clinical, and preclinical studies suggest that another antidiabetic drug 
(metformin) may lower cancer risk and improve outcomes of cancer in diabetics [124]. Moreover, 
metformin treatment was associated with low recurrence in diabetic patients with cervical lymph node 
metastasis of DTC [125].  
The molecular mechanisms at the base of the antineoplastic effect of metformin remain controversial. 
Different mechanisms have been suggested, in fact metformin: a-can act on mitochondria, inhibiting 
complex I; b-can activate AMPK and Redd1 proteins, inhibiting the mTOR pathway cell cycle arrest, 
inducing autophagy, apoptosis and cell death; c-alters the methionine and folate cycles, with a decrease in 
nucleotide synthesis [126]. 
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CXCL8 is a chemokine previously shown to play relevant tumor promoting effects in TC 
microenvironment [127,128]. For this reason, pharmacological strategies aimed at modulating the 
concentration of this chemokine were tested. PGZ was demonstrated to inhibit the TNF-α induced 
CXCL8 secretion in endometriotic stromal cells [129] and to suppress CXCL8 mRNA expression in 
pancreatic cancer cell lines [130]. As far as TC is concerned, it was recently demonstrated that 
metformin, among its anti-tumor effects [131], is able to inhibit the TNF-α-induced CXCL8 secretion in 
primary cultures of normal and PTC cells [132]. The demonstration that metformin and PGZ besides an 
overall similar efficacy in the control of hyperglycemia display some differences in their anti-
inflammatory activity could make it worth to evaluate the combined effects of these two compounds also 
in terms of CXCL8 secretion [133]. 
In ATC, Hayashi et al. showed the expression of both PPARγ gene and protein in 5 human cell lines [134] than 
in PTC cells. Cell proliferation was reduced by PPARγ agonists inducing apoptosis. Moreover, PPARγ agonists 
decreased the invasive potential of the 5 ATC cell lines [134].  
Aiello et al. [135] studied the biologic effects of CGZ and RGZ in ATC cell lines, and demonstrated that RGZ 
increased the expression of thyroid-specific markers of differentiation. 
Marlow et al. [136] showed that, the high-affinity PPARγ agonist RS5444, reactivating suppressed RhoB, 
induced the cyclin-dependent kinase inhibitor p21 and inhibited ATC cells proliferation.  
Recently, Antonelli et al. have shown that PGZ and RGZ can reduce cell growth and proliferation in human 
ATC primary cultured cells, from different patients [137]. Moreover, in another in vitro study it was shown that 
the results of chemosensitivity tests with PPARγ agonists in primary ATC cells obtained directly from fine-
needle aspiration are similar to those obtained from biopsies [138,139].  
A recent paper showed that TZDs are able to modulate chemokine secretion also in ATC. In fact, ATC cells 
produced CXCL10 basally and stimulated by cytokines. However, the pattern of modulation by IFN-γ, TNF-α 
or TZDs was extremely variable, suggesting that the intracellular pathways involved in the chemokine 
modulation in ATC have different types of deregulation with respect to DTC and control TFC [140]. 
More recently a phase I study [141] was conducted on 15 ATC patients, to determine the potential effectiveness 
of paclitaxel and EFA at different doses (7 of them received 0.15 mg, 6 received 0.3 mg, 2 received 0.5 mg of 
EFA). One subject, treated with 0.3 mg of EFA, had a PR; 7 patients had SD. The median times to progression 
in patients treated with 0.15 mg and 0.3 mg of EFA, were 48 and 68 days, while the median survival were 98 
versus 138 days, respectively. Adverse events grade 3 or greater related to the treatment were observed in 10 
subjects. This study suggested that the combination between EFA and paclitaxel was safe and tolerated and had 
biologic activity [141]. 
 
Conclusion 
Recent studies have shown that PPARγ is over-expressed in many tumor types, including those from breast, 
lung, pancreas, colon, glioblastoma, prostate, and DTCs and ATCs. These data suggest a role of PPARγ in 
tumor development and/or progression. PPARγ is emerging as a growth-limiting and differentiation-promoting 
factor, and it exerts a tumor suppressor role. 
Moreover, naturally-occurring and synthetic PPARγ agonists promote growth inhibition and apoptosis. TZDs 
are synthetic agonists of PPARγ that were developed to treat type II diabetes. These compounds also display 
anticancer effects which appear mainly to be independent of their PPARγ agonist activity. Various preclinical 
and clinical studies strongly suggest a role for TZDs both alone and in combination with existing 
chemotherapeutic agents, for the treatment of cancer.  
Differentiation therapy involves the use of agents with the ability to induce differentiation in cells that have lost 
this ability, i.e. cancer cells, targeting pathways capable of re-activating blocked terminal differentiation 
programs. PPARγ agonists have been shown to induce differentiation in solid tumors such as TCs and sarcomas. 
However, emerging data suggest that chronic use of TZDs is associated with increased risk of adverse 
cardiovascular events. The exploration of newer PPARγ agonists can help in unveiling the underlying 
mechanisms of these drugs, providing new molecules that are able to treat cancer, without increasing the 
cardiovascular risk of neoplastic patients. 
10 
CONFLICT OF INTEREST 
 






[1] Chandra, V.; Huang, P.; Hamuro, Y.; Raghuram, S.; Wang, Y.; Burris, T.P.; Rastinejad, F. Structure of the 
intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature, 2008, 456(7220), 350-356. 
[2] Jones, J.R.; Barrick, C.; Kim, K.A.; Lindner, J.; Blondeau, B.; Fujimoto, Y.; Shiota, M.; Kesterson, R.A.; 
Kahn, B.B.; Magnuson, M.A. Deletion of PPARgamma in adipose tissues of mice protects against high fat 
diet-induced obesity and insulin resistance. Proc. Natl. Acad. Sci.USA, 2005, 102(17), 6207-6212. 
[3] Fajas, L.; Auboeuf, D.; Raspé, E.; Schoonjans, K.; Lefebvre, A.M.; Saladin, R.; Najib, J.; Laville, M.; 
Fruchart, J.C.; Deeb, S.; Vidal-Puig, A.; Flier, J.; Briggs, M.R.; Staels, B.; Vidal, H.; Auwerx, J. The 
organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem., 1997, 
272(30), 18779-18789. 
[4] Li, Y.; Qi, Y.; Huang, T.H.; Yamahara, J.; Roufogalis, B.D. Pomegranate flower: a unique traditional 
antidiabetic medicine with dual PPAR-alpha/-gamma activator properties. Diabetes. Obes. Metab., 2008, 
10(1), 10-17. 
[5] Hamblin, M.; Chang, L.; Fan, Y.; Zhang, J.; Chen, Y.E. PPARs and the cardiovascular system. Antioxid. 
Redox. Signal., 2009, 11(6), 1415-1452.  
[6] Khateeb, J.; Gantman, A.; Kreitenberg, A.J.; Aviram, M.; Fuhrman, B. Paraoxonase 1 (PON1) expression 
in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-gamma pathway. 
Atherosclerosis, 2010, 208(1), 119-125. 
[7] Ferrari, S.M.; Fallahi, P.; Vita, R.; Antonelli, A.; Benvenga, S. Peroxisome Proliferator-Activated 
Receptor- γ in Thyroid Autoimmunity. PPAR. Res., 2015, 2015, 232818. 
[8] Wei, S.; Yang, J.; Lee, S.L.; Kulp, S.K.; Chen, C.S. PPARgamma-independent antitumor effects of 
thiazolidinediones. Cancer Lett., 2009, 276(2), 119-124.  
[9] Kroll, T.G.; Sarraf, P.; Pecciarini, L.; Chen, C.J.; Mueller, E.; Spiegelman, B.M.; Fletcher, J.A. PAX8-
PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science, 2000, 289(5483), 1357-
1360. 
[10] Santini, E.; Fallahi, P.; Ferrari, S.M.; Masoni, A.; Antonelli, A.; Ferrannini, E.  Effect of PPAR-gamma 
activation and inhibition on glucose-stimulated insulin release in INS-1e cells. Diabetes, 2004,   53 Suppl 
3:S79-83.  
[11] Antonelli, A.; Ferrari, S.M.; Frascerra, S.; Pupilli, C.; Mancusi, C.; Metelli, M.R.; Orlando, C.; Ferrannini, 
E.; Fallahi, P.  CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated 
receptor-alpha agonists secretion in Graves' and normal thyrocytes. J. Clin. Endocrinol. Metab., 2010, 
95(12), E413-420.   
[12] Antonelli, A.; Ferrari, S.M.; Fallahi, P.; Ghiri, E.; Crescioli, C.; Romagnani, P.; Vitti, P.; Serio, M.; 
Ferrannini, E.  Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human 
thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine, 2010, 
50(3), 260-267.  
[13] Atanasov, A.G.; Wang, J.N.; Gu, S.P.; Bu, J.; Kramer, M.P.; Baumgartner, L.; Fakhrudin, N.; Ladurner, 
A.; Malainer, C.; Vuorinen, A.; Noha, S.M.; Schwaiger, S.; Rollinger, J.M.; Schuster, D.; Stuppner, H.; 
Dirsch, V.M.; Heiss, E.H. Honokiol: a non-adipogenic PPARγ agonist from nature. Biochim. Biophys. 
Acta., 2013, 1830(10), 4813-4819. 
[14] Atanasov, A.G.; Blunder, M.; Fakhrudin, N.; Liu, X.; Noha, S.M.; Malainer, C.; Kramer, M.P.; Cocic, A.; 
Kunert, O.; Schinkovitz, A.; Heiss, E.H.; Schuster, D.; Dirsch, V.M.; Bauer, R. Polyacetylenes from 
Notopterygium incisum--new selective partial agonists of peroxisome proliferator-activated receptor-
gamma. PLoS One, 2013, 8(4), e61755. 
[15] Home, P.D.; Pocock, S.J.; Beck-Nielsen, H.; Curtis, P.S.; Gomis, R.; Hanefeld, M.; Jones, N.P.; Komajda, 
M.; McMurray, J.J.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral 
agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. 
Lancet, 2009, 373(9681), 2125-2135. 
[16] Monami, M.; Lamanna, C.; Marchionni, N.; Mannucci, E. Rosiglitazone and risk of cancer: a meta-
analysis of randomized clinical trials. Diabetes Care, 2008, 31(7), 1455-1460. 
[17] Colmers, I.N.; Bowker, S.L.; Johnson, J.A. Thiazolidinedione use and cancer incidence in type 2 diabetes: 
a systematic review and meta-analysis. Diabetes Metab., 2012, 38(6), 475-484. 
12 
[18] Lin, H.C.; Hsu, Y.T.; Kachingwe, B.H.; Hsu, C.Y.; Uang, Y.S.; Wang, L.H. Dose effect of 
thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort 
study. J. Clin. Pharm. Ther., 2014, 39(4), 354-360. 
[19] Mueller, E.; Smith, M.; Sarraf, P.; Kroll, T.; Aiyer, A.; Kaufman, D.S.; Oh, W.; Demetri, G.; Figg, W.D.; 
Zhou, X.P.; Eng, C.; Spiegelman, B.M.; Kantoff, P.W. Effects of ligand activation of peroxisome 
proliferator-activated receptor gamma in human prostate cancer. Proc. Natl. Acad. Sci. USA, 2000, 97(20), 
10990-10995. 
[20] Kopelovich, L.; Fay, J.R.; Glazer, R.I.; Crowell, J.A. Peroxisome proliferator-activated receptor 
modulators as potential chemopreventive agents. Mol. Cancer Ther., 2002, 1(5), 357-363.  
[21] Koeffler, H.P. Peroxisome proliferator-activated receptor gamma and cancers. Clin. Cancer Res., 2003, 
9(1), 1-9. 
[22] Grommes, C.; Landreth, G.E.; Heneka, M.T. Antineoplastic effects of peroxisome proliferator-activated 
receptor gamma agonists. Lancet Oncol., 2004, 5(7), 419-429.  
[23] Jiang, M.; Shappell, S.B.; Hayward, S.W. Approaches to understanding the importance and clinical 
implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate 
cancer. J. Cell. Biochem., 2004, 91(3), 513-527.  
[24] Weng, J.R.; Chen, C.Y.; Pinzone, J.J.; Ringel, M.D.; Chen C.S. Beyond peroxisome proliferator-activated 
receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr. Relat. 
Cancer, 2006, 13(2), 401-413. 
[25] Demetri, G.D.; Fletcher, C.D.; Mueller, E.; Sarraf, P.; Naujoks, R.; Campbell, N.; Spiegelman, B.M.; 
Singer, S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-
gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. U S A, 1999, 96(7), 3951-
3956. 
[26] Hisatake, J.I.; Ikezoe, T.; Carey, M.; Holden, S.; Tomoyasu, S.; Koeffler, H.P. Down-Regulation of 
prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in 
human prostate cancer. Cancer Res., 2000, 60(19), 5494-5498.  
[27] Gupta, R.A.; Brockman, J.A.; Sarraf, P.; Willson, T.M.; DuBois, R.N. Target genes of peroxisome 
proliferator-activated receptor gamma in colorectal cancer cells. J. Biol. Chem., 2001; 276(32), 29681-
29687. 
[28] Shiau, C.W.; Yang, C.C.; Kulp, S.K.; Chen, K.F.; Chen, C.S.; Huang, J.W.; Chen, C.S. Thiazolidenediones 
mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions 
independently of PPARgamma. Cancer Res., 2005, 65(4), 1561-1569. 
[29] Huang, J.W.; Shiau, C.W.; Yang, Y.T.; Kulp, S.K.; Chen, K.F.; Brueggemeier, R.W.; Shapiro, C.L.; Chen, 
C.S. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by 
thiazolidinediones and their derivatives in breast cancer cells. Mol. Pharmacol., 2005, 67(4), 1342-1348. 
[30] Liu, H.; Zang, C.; Fenner, M.H.; Liu, D.; Possinger, K.; Koeffler, H.P.; Elstner, E. Growth inhibition and 
apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with 
the dual PPARalpha/gamma ligand TZD18. Blood, 2006, 107(9), 3683-3692.  
[31] Plissonnier, M.L.; Fauconnet, S.; Bittard, H.; Lascombe, I. Insights on distinct pathways of 
thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL- sensitive or -resistant malignant 
urothelial cells. Int. J. Cancer, 2010, 127(8), 1769-1784.  
[32] Plissonnier, M.L.; Fauconnet, S.; Bittard, H.; Lascombe, I. The antidiabetic drug ciglitazone induces high 
grade bladder cancer cells apoptosis through the up-regulation of TRAIL. PLoS. One, 2011, 6(12), e28354.  
[33] Colin-Cassin, C.; Yao, X.; Cerella, C.; Chbicheb, S.; Kuntz, S.; Mazerbourg, S.; Boisbrun, M.; Chapleur, 
Y.; Diederich, M.; Flament, S.; Grillier-Vuissoz, I. PPARgamma-inactive ∆2-troglitazone independently 
triggers ER stress and apoptosis in breast cancer cells. Mol. Carcinog., 2013, 54(5), 393-404. 
[34]   Zang, C.; Liu, H.; Bertz, J.; Possinger, K.; Koeffler, H.P.; Elstner, E.; Eucker, J. Induction of endoplasmic 
reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor 
alpha/gamma, in human breast cancer cells. Mol. Cancer. Ther., 2009, 8(8), 2296-2307.  
[35]  Fujita, M.; Yagami, T.; Fujio, M.; Tohji, C.; Takase, K.; Yamamoto, Y.; Sawada, K.; Yamamori, M.; 
Okamura, N. Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway 
in renal cell carcinoma. Cancer Lett., 2011, 312(2), 219-227.  
[36]  Mieczkowska, A.; Baslé, M.F.; Chappard, D.; Mabilleau, G. Thiazolidinediones induce osteocyte 
apoptosis by a G protein-coupled receptor 40-dependent mechanism. J. Biol. Chem., 2012, 287(28), 23517-
23526.  
[37] Wang, D.; Chu, P.C.; Yang, C.N.; Yan, R.; Chuang, Y.C.; Kulp, S.K.; Chen, C.S. Development of a novel 
13 
class of glucose transporter inhibitors. J. Med. Chem., 2012, 55(8), 3827-3836. 
[38]  Lee, K.H.; Hsu, E.C.; Guh, J.H.; Yang, H.C.; Wang, D.; Kulp, S.K.; Shapiro, C.L.; Chen, C.S. Targeting 
energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine 
monophosphate-activated protein kinase (AMPK) activator. J. Biol. Chem., 2011, 286(45), 39247-39258.  
[39] Lu, M.; Kwan, T.; Yu, C.; Chen, F.; Freedman, B.; Schafer, J.M.; Lee, E.J.; Jameson, J.L.; Jordan, V.C.; 
Cryns, V.L. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced ap- 
optosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J. Biol. Chem., 2005, 
280(8), 6742-6751.  
[40] Schultze, K.; Böck, B.; Eckert, A.; Oevermann, L.; Ramacher, D.; Wiestler, O.; Roth, W. Troglitazone 
sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis, 
2006, 11(9), 1503-1512.  
[41] Zou, W.; Liu, X.; Yue, P.; Khuri, F.R.; Sun, S.Y. PPARgamma ligands enhance TRAIL-induced apoptosis 
through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol. Ther., 
2007, 6(1), 99-106. 
[42] Kim, Y.H.; Jung, E.M.; Lee, T.J.; Kim, S.H.; Choi, Y.H.; Park, J.W.; Park, J.W.; Choi, K.S.; Kwon, T.K. 
Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by 
reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free 
Radic. Biol. Med., 2008, 44(6), 1055-1068. 
[43] Kuntz, S.; Mazerbourg, S.; Boisbrun, M.; Cerella, C.; Diederich, M.; Grillier-Vuissoz, I.; Flament, S. 
Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and 
thiazolidinediones. Biochem. Pharmacol., 2014, 92(1), 102-111. 
[44] Jin, X.; Yuan, D.; Chen, X.; Jiang, X. [AMP-activated protein kinase-alpha is involved in the autophagy 
and apoptosis caused by troglitazone]. Wei Sheng Wu Xue Bao., 2012, 52(7), 840-849. 
[45] Yan, J.; Yang, H.; Wang, G.; Sun, L.; Zhou, Y.; Guo, Y.; Xi, Z.; Jiang, X. Autophagy augmented by 
troglitazone is independent of EGFR transactivation and correlated with AMP-activated protein kinase 
signaling. Autophagy, 2010, 6(1), 67-73. 
[46] Zhou, J.; Zhang, W.; Liang, B.; Casimiro, M.C.; Whitaker-Menezes, D.; Wang, M.; Lisanti, M.P.; Lanza-
Jacoby, S.; Pestell, R.G.; Wang, C. PPARgamma activation induces autophagy in breast cancer cells. Int. 
J. Biochem. Cell. Biol., 2009, 41(11), 2334-2342. 
[47] Cerquetti, L.; Sampaoli, C.; Amendola, D.; Bucci, B.; Masuelli, L.; Marchese, R.; Misiti, S.; De Venanzi, 
A.; Poggi, M.; Toscano, V.; Stigliano, A. Rosiglitazone induces autophagy in H295R and cell cycle 
deregulation in SW13 adrenocortical cancer cells. Exp. Cell. Res., 2011, 317(10), 1397-1410. 
[48] Sohn, Y.S.; Tamir, S.; Song, L.; Michaeli, D.; Matouk, I.; Conlan, A.R.; Harir, Y.; Holt, S.H.; Shulaev, V.; 
Paddock, M.L.; Hochberg, A.; Cabanchick, I.Z.; Onuchic, J.N.; Jennings, P.A.; Nechushtai, R.; Mittler, R. 
NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial 
homeostasis and promoting tumor growth. Proc. Natl. Acad. Sci. U S A, 2013, 110(36), 14676-14681. 
[49] Tamir, S.; Zuris, J.A.; Agranat, L.; Lipper, C.H.; Conlan, A.R.; Michaeli, D.; Harir, Y.; Paddock, M.L.; 
Mittler, R.; Cabantchik, Z.I.; Jennings, P.A.; Nechushtai, R. Nutrient-deprivation autophagy factor-1 
(NAF-1): biochemical properties of a novel cellular target for anti-diabetic drugs. PLoS. One, 2013, 8(5), 
e61202. 
[50] Geldenhuys, W.J.; Funk, M.O.; Awale, P.S.; Lin, L.; Carroll, R.T. A novel binding assay identifies high 
affinity ligands to the rosiglitazone binding site of mitoNEET. Bioorg. Med. Chem. Lett., 2011, 21(18), 
5498-5501. 
[51] Wiley, S.E.; Murphy, A.N.; Ross, S.A.; van der Geer, P.; Dixon, J.E. MitoNEET is an iron-containing 
outer mitochondrial membrane protein that regulates oxidative capacity. Proc. Natl. Acad. Sci. U S A, 
2007, 104(13), 5318-5323. 
[52] Guh, J.H.; Chang, W.L.; Yang, J.; Lee, S.L.; Wei, S.; Wang, D.; Kulp, S.K.; Chen, C.S. Development of 
novel adenosine monophosphate-activated protein kinase activators. J. Med. Chem., 2010, 53(6), 2552-
2561.  
[53] Wei, S.; Yang, H.C.; Chuang, H.C.; Yang, J.; Kulp, S.K.; Lu, P.J.; Lai, M.D.; Chen, C.S. A novel 
mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. 
J. Biol. Chem., 2008, 283(39), 26759-26770. 
[54] Wei, S.; Lin, L.F.; Yang, C.C.; Wang, Y.C.; Chang, G.D.; Chen, H.; Chen, C.S. Thiazolidinediones 
modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box 
proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-
activated receptor gamma. Mol. Pharmacol., 2007, 72(3), 725-733. 
14 
[55] Arafa, el-S.A.; Abdelazeem, A.H.; Arab, H.H.; Omar, H.A. OSU-CG5, a novel energy restriction mimetic 
agent, targets human colorectal cancer cells in vitro. Acta. Pharmacol. Sin., 2014, 35(3), 394-400. 
[56] Lecomte, J.; Flament, S.; Salamone, S.; Boisbrun, M.; Mazerbourg, S.; Chapleur, Y.; Grillier-Vuissoz, I. 
Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-
independent events in two hormone-dependent breast cancer cell lines. Breast Cancer Res. Treat., 2008, 
112(3), 437-451. 
[57] Colin, C.; Salamone, S.; Grillier-Vuissoz, I.; Boisbrun, M.; Kuntz, S.; Lecomte, J.; Chapleur, Y.; Flament, 
S. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative 
effect in both hormone-dependent and hormone-independent breast cancer cell lines. Breast Cancer Res. 
Treat., 2010, 124(1), 101-110.  
[58] Salamone, S.; Colin, C.; Grillier-Vuissoz, I.; Kuntz, S.; Mazerbourg, S.; Flament, S.; Martin, H.; Richert, 
L.; Chapleur, Y.; Boisbrun, M. Synthesis of new troglitazone derivatives: anti-proliferative activity in 
breast cancer cell lines and preliminary toxicological study. Eur. J. Med. Chem., 2012, 51, 206-215.  
[59] Yang, J.; Wei, S.; Wang, D.S.; Wang, Y.C.; Kulp, S.K.; Chen, C.S. Pharmacological exploitation of the 
peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen 
receptor-ablative agents. J. Med. Chem., 2008, 51(7), 2100-2107.  
[60] Berman-Booty, L.D.; Chu, P.C.; Thomas-Ahner, J.M.; Bolon, B.; Wang, D.; Yang, T.; Clinton, S.K.; Kulp, 
S.K.; Chen, C.S. Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in 
transgenic mice by a new energy restriction-mimetic agent. Cancer Prev. Res. (Phila)., 2013, 6(3), 232-
241. 
[61] Nakles, R.E.; Kallakury, B.V.; Furth, P.A. The PPAR-γ agonist efatutazone increases the spectrum of well- 
differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 
haploinsufficiency. Am. J. Pathol., 2013, 182(6), 1976-1985. 
[62] Shimazaki, N.; Togashi, N.; Hanai, M.; Isoyama, T.; Wada, K.; Fujita, T.; Fujiwara, K.; Kurakata, S. Anti-
tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of 
thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur. J. 
Cancer, 2008, 44(12), 1734-1743. 
[63] Fröhlich, E.; Wahl, R. Chemotherapy and chemoprevention by thiazolidinediones. Biomed. Res. Int., 2015, 
2015:845340. 
[64] Debrock, G.; Vanhentenrijk, V.; Sciot, R.; Debiec-Rychter, M.; Oyen, R.; Van Oosterom, A. A phase II 
trial with rosiglitazone in liposarcoma patients. Br. J. Cancer, 2003, 89(8), 1409-1412.  
[65]  Dai, Y.; Wang, W.H. Peroxisome proliferator-activated receptor γ and colorectal cancer. World J. 
Gastrointest. Oncol., 2010, 2(3), 159-164.  
[66] Pancione, M.; Forte, N.; Sabatino, L.; Tomaselli, E.; Parente, D.; Febbraro, A.; Colantuoni, V. Reduced 
beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with 
colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 
2, and patient outcome. Hum. Pathol., 2009, 40(5), 714-725.  
[67] Theocharis, S.; Giaginis, C.; Parasi, A.; Margeli, A.; Kakisis, J.; Agapitos, E.; Kouraklis, G. Expression of 
peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological 
parameters, cell cycle-related molecules, and patients’ survival. Dig. Dis. Sci., 2007, 52(9), 2305-2311.  
[68] Gustafsson, A.; Hansson, E.; Kressner, U.; Nordgren, S.; Andersson, M.; Wang, W.; Lönnroth, C.; 
Lundholm, K. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in 
prediction of disease-specific mortality. Int. J. Cancer, 2007, 121(2), 232-240.  
[69] Osawa, E.; Nakajima, A.; Wada, K.; Ishimine, S.; Fujisawa, N.; Kawamori, T.; Matsuhashi, N.; Kadowaki, 
T.; Ochiai, M.; Sekihara, H.; Nakagama, H. Peroxisome proliferator-activated receptor gamma ligands 
suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology, 2003, 124(2), 361-
367.  
[70] Yoshizumi, T.; Ohta, T.; Ninomiya, I.; Terada, I.; Fushida, S.; Fujimura, T.; Nishimura, G.; Shimizu, K.; 
Yi, S.; Miwa, K. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits 
growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int. J. 
Oncol., 2004, 25(3), 631-639.  
[71] Choi, I.K.; Kim, Y.H.; Kim, J.S.; Seo, J.H. PPAR-gamma ligand promotes the growth of APC-mutated 
HT-29 human colon cancer cells in vitro and in vivo. Invest. New Drugs, 2008, 26(3), 283-288.  
[72] Tsukahara, T.; Haniu, H. Peroxisome proliferator-activated receptor gamma overexpression suppresses 
proliferation of human colon cancer cells. Biochem. Biophys. Res. Commun., 2012, 424(3), 524-529.  
[73] Kulke, M.H.; Demetri, G.D.; Sharpless, N.E.; Ryan, D.P.; Shivdasani, R.; Clark, J.S.; Spiegelman, B.M.; 
Kim, H.; Mayer, R.J.; Fuchs, C.S. A phase II study of troglitazone, an activator of the PPARgamma 
15 
receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J., 2002, 8(5), 395-
399. 
[74] Theocharis, S.; Kanelli, H.; Politi, E.; Margeli, A.; Karkandaris, C.; Philippides, T.; Koutselinis, A. 
Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: 
correlation with histological type and grade. Lung Cancer, 2002, 36(3), 249-255.  
[75] Sasaki, H.; Tanahashi, M.; Yukiue, H.; Moiriyama, S.; Kobayashi, Y.; Nakashima, Y.; Kaji, M.; Kiriyama, 
M.; Fukai, I.; Yamakawa, Y.; Fujii, Y. Decreased perioxisome proliferator-activated receptor gamma gene 
expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer, 2002, 36(1), 71-
76.  
[76] Lyon, C.M.; Klinge, D.M.; Do, K.C.; Grimes, M.J.; Thomas, C.L.; Damiani, L.A.; March, T.H.; Stidley, 
C.A.; Belinsky, S.A. Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. 
Carcinogenesis, 2009, 30(12), 2095-2099. 
[77] Jiang, W.G.; Douglas-Jones, A.; Mansel, R.E. Expression of peroxisome-proliferator activated receptor-
gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with 
clinical outcomes. Int. J. Cancer, 2003, 106(5), 752-757. 
[78] Magenta, G.; Borenstein, X.; Rolando, R.; Jasnis, M.A. Rosiglitazone inhibits metastasis development of a 
murine mammary tumor cell line LMM3. BMC Cancer, 2008, 8, 47. 
[79] Bojková, B.; Garajová, M.; Kajo, K.; Péc, M.; Kubatka, P.; Kassayová, M.; Kisková, T., Orendás, P.; 
Ahlersová, E.; Ahlers, I. Pioglitazone in chemically induced mammary carcinogenesis in rats. Eur. J. 
Cancer Prev., 2010, 19(5), 379-384. 
[80] Burstein, H.J.; Demetri, G.D.; Mueller, E.; Sarraf, P.; Spiegelman, B.M.; Winer, E.P. Use of the 
peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory 
breast cancer: a phase II study. Breast Cancer Res. Treat., 2003, 79(3), 391-397. 
[81] Yee, L.D.; Williams, N.; Wen, P.; Young, D.C.; Lester, J.; Johnson, M.V.; Farrar, W.B.; Walker, M.J.; 
Povoski, S.P.; Suster, S.; Eng, C. Pilot study of rosiglitazone therapy in women with breast cancer: effects 
of short-term therapy on tumor tissue and serum markers. Clin. Cancer Res., 2007, 13(1), 246-252. 
[82] Nakamura, Y.; Suzuki, T.; Sugawara, A.; Arai, Y.; Sasano, H. Peroxisome proliferator-activated receptor 
gamma in human prostate carcinoma. Pathol. Int., 2009, 59(5), 288-293. 
[83] Annicotte, J.S.; Iankova, I.; Miard, S.; Fritz, V.; Sarruf, D.; Abella, A.; Berthe, M.L.; Noël, D.; Pillon, A.; 
Iborra, F.; Dubus, P.; Maudelonde, T.; Culine, S.; Fajas, L. Peroxisome proliferator-activated receptor 
gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol. Cell. 
Biol., 2006, 26(20), 7561-7574. 
[84] Kato, M.; Nagaya, T.; Fujieda, M.; Saito, K.; Yoshida, J.; Seo, H. Expression of PPARgamma  and its 
ligand-dependent growth inhibition in human brain tumor cell lines. Jpn. J. Cancer Res., 2002, 93(6), 660-
666. 
[85] Grommes, C.; Conway, D.S.; Alshekhlee, A.; Barnholtz-Sloan, J.S. Inverse association of PPARγ agonists 
use and high grade glioma development. J. Neurooncol., 2010, 100(2), 233-239. 
[86] Grommes, C.; Karlo, J.C.; Caprariello, A.; Blankenship, D.; Dechant, A.; Landreth, G.E. The PPARγ 
agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft 
model. Cancer Chemother. Pharmacol., 2013, 71(4), 929-936. 
[87] Hau, P.; Kunz-Schughart, L.; Bogdahn, U.; Baumgart, U.; Hirschmann, B.; Weimann, E,.; Muhleisen, H.; 
Ruemmele, P.; Steinbrecher, A.; Reichle, A. Low-dose chemotherapy in combination with COX-2 
inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. Oncology, 2007, 
73(1-2), 21-25. 
[88] Meyer, S.; Vogt, T.; Landthaler, M.; Berand, A.; Reichle, A.; Bataille, F.; Marx, A.H.; Menz, A.; 
Hartmann, A.; Kunz-Schughart, L.A.; Wild, P.J. Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-
Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. 
PPAR. Res., 2009, 2009, 848645.  
[89] Ferrara, A.; Lewis, J.D.; Quesenberry, C.P. Jr.; Peng, T.; Strom, B.L.; Van Den Eeden, S.K.; Ehrlich, S.F.; 
Habel, L.A. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care, 
2011, 34(4), 923-929.  
[90] Botton, T.; Puissant, A.; Bahadoran, P.; Annicotte, J.S.; Fajas, L.; Ortonne, J.P.; Gozzerino, G.; Zamoum, 
T.; Tartare-Deckert, S.; Bertolotto, C.; Ballotti, R.; Rocchi, S. In vitro and in vivo anti-melanoma effects of 
ciglitazone. J. Invest. Dermatol., 2009, 129(5), 1208-1218. 
[91] Ondrey, F. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: 
implications for chemoprevention. Clin. Cancer Res., 2009, 15(1), 2-8.  
16 
[92] Omur, O.; Baran, Y. An update on molecular biology of thyroid cancers. Crit. Rev. Oncol. Hematol., 2014, 
90(3), 233-252.  
[93] Li, N.; Du, X.L.; Reitzel, L.R.; Xu, L.; Sturgis, E.M. Impact of enhanced detection on the increase in 
thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within 
the surveillance, epidemiology, and end results registry, 1980-2008. Thyroid, 2013, 23(1), 103-110. 
[94] Schlumberger, M.; Chevillard, S.; Ory, K.; Dupuy, C.; Le Guen, B.; de Vathaire, F. [Thyroid cancer 
following exposure to ionising radiation]. Cancer Radiother., 2011, 15(5), 394-399.  
[95] Antonelli, A.; Miccoli, P.; Derzhitski, V.E.; Panasiuk, G.; Solovieva, N.; Baschieri, L. Epidemiologic and 
clinical evaluation of thyroid cancer in children from the Gomel region (Belarus). World J. Surg., 1996, 
20(7), 867-871. 
[96] Zimmermann, M.B.; Boelaert, K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol., 
2015, 3(4), 286-295. 
[97] Jankovic, B.; Le, K.T.; Hershman, J.M. Clinical Review: Hashimoto's thyroiditis and papillary thyroid 
carcinoma: is there a correlation? J. Clin. Endocrinol. Metab., 2013, 98(2), 474-482.  
[98] Antonelli, A.; Delle Sedie, A.; Fallahi, P.; Ferrari, S.M., Maccheroni, M.; Ferrannini, E.; Bombardieri, S.; 
Riente, L. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. 
J. Rheumatol., 2006, 33(10), 2026-2028. 
[99] Antonelli, A.; Ferri, C.; Fallahi, P.; Pampana, A.; Ferrari, S.M.; Barani, L.; Marchi, S.; Ferrannini, E. 
Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid, 2007, 17(5), 447-
451. 
[100] Antonelli, A.; Ferri, C.; Fallahi, P.; Nesti, C.; Zignego, A.L.; Maccheroni, M. Thyroid cancer in HCV-
related mixed cryoglobulinemia patients. Clin. Exp. Rheumatol., 2002, 20(5), 693-696. 
[101] Antonelli, A.; Ferri, C.; Fallahi, P.; Cazzato, M.; Ferrari, S.M.; Sebastiani, M.; Ferrannini, E. Clinical 
and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur. J. Endocrinol.,  2007, 156(4), 
431-437.  
[102] Eustatia-Rutten, C.F.; Corssmit, E.P.; Biermasz, N.R.; Pereira, A.M.; Romijn, J.A.; Smit, J.W. Survival 
and death causes in differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab., 2006, 91(1), 313-319.  
[103] Durante, C.; Haddy, N.; Baudin, E.; Leboulleux, S.; Hartl, D.; Travagli, J.P.; Caillou, B.; Ricard, M.; 
Lumbroso, J.D.; De Vathaire, F.; Schlumberger, M. Long-term outcome of 444 patients with distant 
metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. 
Clin. Endocrinol. Metab., 2006, 91(8), 2892-2899.  
[104] Dohán, O.; De la Vieja, A.; Paroder, V.; Riedel, C.; Artani, M.; Reed, M.; Ginter, C.S.; Carrasco, N. 
The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr. Rev., 
2003, 24(1), 48-77.  
[105] Schlumberger, M.J. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical 
perspective and current status. J. Endocrinol. Invest., 1999, 22(11), 3-7.  
[106] Carling, T.; Udelsman, R. Thyroid Tumors. In: Cancer: Principles and Practice of Oncology; DeVita, 
V.T.; Hellman, S.; Rosenberg, S.A.; eds. DeVita, Hellman, and Rosenberg’s. 9th ed.; Lippincott Williams 
& Wilkins: Philadelphia, 2011.  
[107] Versari, A.; Sollini, M.; Frasoldati, A.; Fraternali, A.; Filice, A.; Froio, A.; Asti, M.; Fioroni, F.; 
Cremonini, N.; Putzer, D.; Erba, P.A. Differentiated thyroid cancer: a new perspective with radiolabeled 
somatostatin analogues for imaging and treatment of patients. Thyroid, 2014, 24(4), 715-726.  
[108] Martelli, M.L.; Iuliano, R.; Le Pera, I.; Sama', I.; Monaco, C.; Cammarota, S.; Kroll, T.; Chiariotti, L.; 
Santoro, M.; Fusco, A. Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid 
carcinoma cell growth. J. Clin. Endocrinol. Metab. 2002, 87(10), 4728-4735.  
[109] Fröhlich, E.; Brossart, P.; Wahl, R. Induction of iodide uptake in transformed thyrocytes: a compound 
screening in cell lines. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(5), 780-790.  
[110] Park, J.W.; Zarnegar, R.; Kanauchi, H.; Wong, M.G.; Hyun, W.C.; Ginzinger, D.G.; Lobo, M.; Cotter, 
P.; Duh, Q.Y.; Clark, O.H. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, 
induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid, 2005, 15(3), 
222-231.  
[111] Fröhlich, E.; Machicao, F.; Wahl, R. Action of thiazolidinediones on differentiation, proliferation and 
apoptosis of normal and transformed thyrocytes in culture. Endocr. Relat. Cancer, 2005, 12(2), 291-303. 
[112] Dobson, M.E.; Diallo-Krou, E.; Grachtchouk, V.; Yu, J.; Colby, L.A.; Wilkinson, J.E.; Giordano, T.J.; 
Koenig, R.J. Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma 
fusion protein thyroid carcinoma. Endocrinology, 2011, 152(11), 4455-4465. 
[113] Kato, Y.; Ying, H.; Zhao, Y.; Furuya, F.; Araki, O.; Willingham, M.C.; Cheng, S.Y. PPARgamma 
17 
insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB 
signaling pathway. Oncogene, 2006, 25(19), 2736-2747. 
[114] Antonelli, A.; Ferrari, S.M.; Fallahi, P.; Frascerra, S.; Piaggi, S.; Gelmini, S.; Lupi, C.; Minuto, M.; 
Berti, P.; Benvenga, S.; Basolo, F.; Orlando, C.; Miccoli, P. Dysregulation of secretion of CXC alpha-
chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-
gamma agonists. Endocr. Relat. Cancer., 2009, 16(4), 1299-1311.  
[115] Antonelli, A.; Ferrari, S.M.; Corrado, A.; Di Domenicantonio, A.; Fallahi, P. Autoimmune thyroid 
disorders. Autoimmun. Rev., 2015, 14(2), 174-180. 
[116] Rosenbaum-Krumme, S.J.; Bockisch, A.; Nagarajah, J. Pioglitazone therapy in progressive 
differentiated thyroid carcinoma. Nuklearmedizin, 2012, 51(4), 111-115. 
[117]  Elola, M.; Yoldi, A.; Emparanza, J.I.; Matteucci, T.; Bilbao, I.; Goena, M. [Redifferentiation therapy 
with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of 
radioiodine uptake]. Rev. Esp. Med. Nucl. 2011, 30(4), 241-243. 
[118]  Elias, A.N.; Lizotte, P. Enhanced radioiodine uptake in a patient with poorly differentiated papillary 
thyroid cancer after treatment with rosiglitazone. Clin. Nucl. Med., 2006, 31(9), 517-519. 
[119]  Philips, J.C.; Petite, C.; Willi, J.P.; Buchegger, F.; Meier, C.A. Effect of peroxisome proliferator-
activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl. Med. Commun., 
2004, 25(12), 1183-1186. 
[120]  Kebebew, E.; Peng, M.; Reiff, E.; Treseler, P.; Woeber, K.A.; Clark, O.H.; Greenspan, F.S.; Lindsay, 
S.; Duh, Q.Y.; Morita, E. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and 
radioiodine-negative differentiated thyroid cancer. Surgery, 2006, 140(6), 960-967. 
[121]  Tepmongkol, S.; Keelawat, S.; Honsawek S.; Ruangvejvorachai, P. Rosiglitazone effect on 
radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a 
correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid, 2008, 18(7), 
697-704. 
[122]  Kebebew, E.; Lindsay, S.; Clark, O.H.; Woeber, K.A.; Hawkins, R.; Greenspan, F.S. Results of 
rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced 
differentiated thyroid cancer. Thyroid, 2009, 19(9), 953-956. 
[123]  Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; 
Arbuck, S.; Gwyther, S.; Mooney, M.; Rubinstein, L.; Shankar, L.; Dodd, L.; Kaplan, R.; Lacombe, D.; 
Verweij, J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. 
J. Cancer, 2009, 45(2), 228-247. 
[124] Leone, A.; Di Gennaro, E.; Bruzzese, F.; Avallone, A.; Budillon, A. New perspective for an old 
antidiabetic drug: metformin as anticancer agent. Cancer Treat. Res., 2014, 159, 355-376.  
[125] Jang, E.K.; Kim, W.G.; Kwon, H.; Choi, Y.M.; Jeon, M.J.; Kim, T.Y.; Shong, Y.K.; Kim, W.B.; 
Kim, E.Y. Metformin Is Associated with a Favorable Outcome in Diabetic Patients with Cervical 
Lymph Node Metastasis of Differentiated Thyroid Cancer. Eur. Thyroid J., 2015, 4(3), 181-188. 
[126] Jara, J.A.; López-Muñoz, R. Metformin and cancer: Between the bioenergetic disturbances and 
the antifolate activity. Pharmacol. Res., 2015, 101, 102-108. 
[127] Rotondi, M.; Coperchini, F.; Pignatti, P.; Sideri, R.; Groppelli, G.; Leporati, P.; La Manna, L.; 
Magri, F.; Mariotti, S.; Chiovato, L. Interferon-γ and Tumor Necrosis Factor-α Sustain Secretion of 
Specific CXC Chemokines in Human Thyrocytes: A First Step Toward a Differentiation between 
Autoimmune and Tumor-Related Inflammation? J. Clin. Endocrinol. Metab., 2013, 98(1), 308-313. 
[128] Rotondi, M.; Coperchini, F.; Chiovato, L. CXCL8 in thyroid disease: From basic notions to 
potential applications in clinical practice. Cytokine Growth Factor Rev., 2013, 24(6), 539-546.  
[129] Ohama, Y.; Harada, T.; Iwabe, T.; Taniguchi, F.; Takenaka, Y.; Terakawa, N. Peroxisome 
proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced 
interleukin-8 production and growth in endometriotic stromal cells. Fertil. Steril., 2008, 89(2), 311-
317. 
[130] Ninomiya, I.; Yamazaki, K.; Oyama, K.; Hayashi, H.; Tajima, H.; Kitagawa, H.; Fushida, S.; 
Fujimura, T.; Ohta, T. Pioglitazone inhibits the proliferation and metastasis of human pancreatic 
cancer cells. Oncol. Lett., 2014, 8(6), 2709-2714. 
[131] Coperchini, F.; Leporati, P.; Rotondi, M.; Chiovato, L. Expanding the therapeutic spectrum of 
metformin: from diabetes to cancer. J. Endocrinol. Invest., 2015, 38(10), 1047-1055. 
[132] Rotondi, M.; Coperchini, F.; Pignatti, P.; Magri, F.; Chiovato, L. Metformin Reverts the 
Secretion of CXCL8 Induced by TNF-α in Primary Cultures of Human Thyroid Cells: An 
Additional Indirect Anti-Tumor Effect of the Drug. J. Clin. Endocrinol. Metab., 2015, 100(3), E427-
18 
32.  
[133] Esteghamati, A.; Rezvani, S.; Khajeh, E.; Ebadi, M.; Nakhjavani, M.; Noshad, S. Comparative 
effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial. J. 
Endocrinol. Invest., 2014, 37(12), 1211-1218. 
[134] Hayashi, N.; Nakamori, S.; Hiraoka, N.; Tsujie, M.; Xundi, X.; Takano, T.; Amino, N.; Sakon, M.; 
Monden, M. Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic 
thyroid carcinoma. Int. J. Oncol., 2004, 24(1), 89-95. 
[135] Aiello, A.; Pandini, G.; Frasca, F.; Conte, E.; Murabito, A.; Sacco, A.; Genua, M.; Vigneri, R.; 
Belfiore, A. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of 
epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology, 2006, 147(9), 4463-
4475. 
[136] Marlow, L.A.; Reynolds, L.A.; Cleland, A.S.; Cooper, S.J.; Gumz, M.L.; Kurakata, S.; Fujiwara, K.; 
Zhang, Y.; Sebo, T.; Grant, C.; McIver, B.; Wadsworth, J.T.; Radisky, D.C.; Smallridge, R.C.; Copland, 
J.A. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer 
growth. Cancer Res., 2009, 69(4), 1536-1544.  
[137] Antonelli, A.; Ferrari, S.M.; Fallahi, P.; Berti, P.; Materazzi, G.; Minuto, M.; Giannini, R.; Marchetti, 
I.; Barani, L.; Basolo, F.; Ferrannini, E.; Miccoli, P. Thiazolidinediones and antiblastics in primary human 
anaplastic thyroid cancer cells. Clin. Endocrinol. (Oxf)., 2009, 70(6), 946-953.  
[138] Antonelli, A.; Ferrari, S.M.; Fallahi, P.; Berti, P.; Materazzi, G.; Marchetti, I.; Ugolini, C.; Basolo, F.; 
Miccoli, P.; Ferrannini, E. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of 
primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur. J. Endocrinol., 2008, 
159(3), 283-291.  
[139] Antonelli, A.; Ferrari, S.M.; Fallahi, P.; Berti, P.; Materazzi, G.; Barani, L.; Marchetti, I.; Ferrannini, 
E.; Miccoli, P. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used 
for chemosensitivity tests. Clin. Endocrinol. (Oxf)., 2008, 69(1), 148-152.  
[140] Antonelli, A.; Ferrari, S.M.; Fallahi, P.; Piaggi, S.; Di Domenicantonio, A.; Galleri, D.; Santarpia, L.; 
Basolo, F.; Ferrannini, E.; Miccoli, P. Variable modulation by cytokines and thiazolidinediones of the 
prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine, 2012, 59(2), 218-222.  
[141] Smallridge, R.C.; Copland, J.A.; Brose, M.S.; Wadsworth, J.T.; Houvras, Y.; Menefee, M.E.; Bible, 
K.C.; Shah, M.H.; Gramza, A.W.; Klopper, J.P.; Marlow, L.A.; Heckman, M.G.; Von Roemeling, R. 
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of 
a multicenter phase 1 trial. J. Clin. Endocrinol. Metab., 2013, 98(6), 2392-2400.  
 
 
  
 
